Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Acquires Preclinical Cardiovascular Antibody In Nearly $200 Million Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will make $15 million up-front payment to BioInvent for North American rights to BI-204.

You may also be interested in...



Roche To Partner With Two European Biotechs On Oncology Candidate

Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.

Roche To Partner With Two European Biotechs On Oncology Candidate

Deal with BioInvent International and ThromboGenics will develop the novel monoclonal antibody TB-403.

Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research

The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.

Topics

UsernamePublicRestriction

Register

PS065003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel